Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
Phase 1 Completed
85 enrolled
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
Phase 1 Completed
20 enrolled
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma
Phase 1 Completed
3 enrolled
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Phase 1 Completed
26 enrolled
CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia
Phase 1 Completed
18 enrolled
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Phase 1 Completed
50 enrolled
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Phase 1 Completed
52 enrolled
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Phase 1 Completed
54 enrolled 24 charts
Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)
Phase 1 Completed
12 enrolled
A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects
Phase 1 Completed
25 enrolled
A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
Phase 1 Completed
10 enrolled
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
Phase 1 Completed
10 enrolled
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Phase 1 Completed
8 enrolled
Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma
Phase 1 Completed
29 enrolled 13 charts
HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Phase 1 Completed
89 enrolled
KEYNOTE-A33
Phase 1 Completed
7 enrolled 13 charts
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Phase 1 Completed
11 enrolled 16 charts
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
Phase 1 Completed
111 enrolled
CAR-37 T Cells in Hematologic Malignancies
Phase 1 Completed
6 enrolled
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
Phase 1 Completed
14 enrolled
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
Phase 1 Completed
72 enrolled
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Phase 1 Completed
154 enrolled
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Phase 1 Completed
18 enrolled
Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
Phase 1 Completed
65 enrolled
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Phase 1 Completed
70 enrolled
A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy
Phase 1 Completed
13 enrolled
A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1 Completed
24 enrolled
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
Phase 1 Completed
27 enrolled
Study of TG-1801 in Subjects With B-Cell Lymphoma
Phase 1 Completed
50 enrolled
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
Phase 1 Completed
23 enrolled 17 charts
Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma
Phase 1 Completed
14 enrolled
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
Phase 1 Completed
34 enrolled
Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell
Phase 1 Completed
26 enrolled 10 charts
Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial
Phase 1 Completed
9 enrolled
T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
Phase 1 Completed
27 enrolled 25 charts
A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Phase 1 Completed
7 enrolled 31 charts
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
Phase 1 Completed
32 enrolled
A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
Phase 1 Completed
41 enrolled
A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas
Phase 1 Completed
12 enrolled
SELINDA
Phase 1 Completed
39 enrolled
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
Phase 1 Completed
44 enrolled
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1
Phase 1 Completed
13 enrolled
A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma
Phase 1 Completed
85 enrolled
Clinical Study of ET190L1 ARTEMISâ„¢ in Relapsed, Refractory B Cell Lymphoma
Phase 1 Completed
4 enrolled
Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
Phase 1 Completed
53 enrolled 19 charts
A Phaseâ… b Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects
Phase 1 Completed
6 enrolled
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Phase 1 Completed
113 enrolled
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Phase 1 Completed
103 enrolled 20 charts
Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation
Phase 1 Completed
6 enrolled
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 Completed
2 enrolled